Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30228283 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTKMT2AMEN1RAB9A | |
| SCHEMBL30228025 | 1.00 | ALDH1A1 (0.46) | ALDH1A1MAPTKMT2AMEN1RAB9A | |
| SCHEMBL30228087 | 0.90 | PRSS1 (0.42) | ALDH1A1KMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL31710454 | 0.90 | PRSS1 (0.42) | ALDH1A1KMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL31711008 | 0.90 | PRSS1 (0.42) | ALDH1A1KMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL30228057 | 0.90 | PRSS1 (0.42) | ALDH1A1KMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL22431780 | 0.88 | MAPT (0.54) | ALDH1A1MAPTKMT2AMEN1RAB9A | |
| SCHEMBL20848098 | 0.88 | MAPT (0.54) | ALDH1A1MAPTKMT2AMEN1RAB9A | |
| SCHEMBL30227990 | 0.88 | ALDH1A1 (0.46) | ALDH1A1MAPTKMT2AMEN1RAB9A | |
| SCHEMBL30360959 | 0.88 | MAPT (0.54) | ALDH1A1MAPTKMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2023034346-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | POLRMT, TFAM, POLM | ALDH1A1 3178/4885MAPT 716/4885KMT2A 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.